Stellar Biotechnologies Inc (SBOT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Stellar Biotechnologies Inc (SBOT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8155
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injectable product to assess immune response. Its products comprise Stellar KLH protein which can be used in various grades, formulations, and configurations for both clinical and research applications and KLH Elisa Kits. Stellar Bio’s products are used in immunotherapies as an immune stimulant in immunotoxicology applications and therapeutic vaccine conjugation. The company partners with research centers and developers of active immunotherapies and therapeutic vaccines. Stellar Bio is headquartered in Port Hueneme, California, the US.

Stellar Biotechnologies Inc (SBOT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Equity Offering 14
Stellar Biotech to Raise USD3 Million in Private Placement of Shares up on Exercise of Warrants 14
Stellar Biotech Raises USD5.5 Million in Public Offering of Units 15
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Asset Transactions 24
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc – Key Competitors 25
Stellar Biotechnologies Inc – Key Employees 26
Stellar Biotechnologies Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Stellar Biotechnologies reports third quarter financial results 28
May 07, 2018: Stellar Biotechnologies Announces Second Quarter Financial Results 30
Feb 07, 2018: Stellar Biotechnologies Reports First Quarter 2018 Financial Results 32
Dec 01, 2017: Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results 33
Aug 09, 2017: Stellar Biotechnologies Reports Third Quarter 2017 Financial Results 34
May 09, 2017: Stellar Biotechnologies Reports Second Quarter 2017 Financial Results 36
Feb 06, 2017: Stellar Biotechnologies Reports First Quarter 2017 Financial Results 38
Corporate Communications 39
Jan 25, 2018: Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors 39
Product News 40
Jun 21, 2018: Stellar Reports Positive Research Results from KLH Glycosylation Study 40
Jan 11, 2017: Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region 41
Other Significant Developments 42
May 24, 2018: Stellar Achieves Robust Viral Clearance for Manufacturing Process 42
Mar 29, 2018: Stellar Biotech Begins Scale-Up and Expansion Project at Port Facility 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Stellar Biotech to Raise USD3 Million in Private Placement of Shares up on Exercise of Warrants 14
Stellar Biotech Raises USD5.5 Million in Public Offering of Units 15
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc, Key Competitors 25
Stellar Biotechnologies Inc, Key Employees 26
Stellar Biotechnologies Inc, Subsidiaries 27
Stellar Biotechnologies Inc, Joint Venture 27

List of Figures
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Stellar Biotechnologies Inc (SBOT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • enGene Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary enGene Inc (enGene) is a biotechnology company that focuses on transforming medicine by administering gene therapy as an oral drug. The company develops a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. It also developed a non-viral gene-therapy platform …
  • Rebiotix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that offers treatment solutions for debilitating diseases by harnessing the power of the human microbiome. The company harnesses microbiota restoration therapy, a drug delivery platform that releases hea …
  • Endologix, Inc. (ELGX)-医療機器分野:企業M&A・提携分析
    Summary Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA p …
  • Medical Transcription Billing Corp (MTBC)-医療機器分野:企業M&A・提携分析
    Summary Medical Transcription Billing Corp (Medical Transcription) is a healthcare IT company that offers web-based solutions and related business services. The company offers electronic health records, practice management software, and patient engagement software. Its products comprise ChartsPro, P …
  • NLC India Ltd (NLCINDIA):電力:M&Aディール及び事業提携情報
    Summary NLC India Limited (NLCIL), formerly Neyveli Lignite Corporation Limited, a Government of India Enterprise, is a mining and power generation company. It operates opencast lignite mines and sources coal to generate electricity. The company generates electricity by using various sources of ener …
  • Cardiatis SA:製品パイプライン分析
    Summary Cardiatis SA (Cardiatis) is a medical device company that develops a multilayer technology platform for endovascular aneurysm. The company offers a three dimensional multilayer braided stent system for endovascular aneurysm repair. Its multilayer flow modulator include aortic, peripheral, bi …
  • Franklin Resources, Inc.:企業のM&A・事業提携・投資動向
    Franklin Resources, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Franklin Resources, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Tobu Railway Co Ltd:戦略・SWOT・企業財務分析
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • A.P. Eagers Limited:戦略・SWOT・企業財務分析
    A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report Summary A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wacoal Holdings Corp (3591):企業の財務・戦略的SWOT分析
    Wacoal Holdings Corp (3591) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MediaTek Inc.:企業の戦略・SWOT・財務情報
    MediaTek Inc. - Strategy, SWOT and Corporate Finance Report Summary MediaTek Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Trimedyne Inc:企業の戦略的SWOT分析
    Trimedyne Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Chevron Corp (CVX):電力:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • Korea Petrochemical Ind. Co Ltd (006650):企業の財務・戦略的SWOT分析
    Summary Korea Petrochemical Ind. Co Ltd (KPICL) is a chemical company that manufactures and markets petrochemical products. The company provides products such as olefins, aromatics, polypropylene, EO and EG, PP and HDPE. It provides olefins products such as ethylene, propylene, butene, butane, isobu …
  • Opthea Ltd (OPT):医療機器:M&Aディール及び事業提携情報
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • MegaChips Corporation (6875):企業の財務・戦略的SWOT分析
    MegaChips Corporation (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tokyo Electron Device Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Andersons Inc (ANDE):企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • DUAL International Ltd:企業の戦略・SWOT・財務情報
    DUAL International Ltd - Strategy, SWOT and Corporate Finance Report Summary DUAL International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆